|
MRI News Service:
'Gadolinium' p5 |
|
|
|
 |
 | | | ''Magnetic resonance imaging (MRI) using gadolinium-based contrast agents is safe in intensive care unit (ICU) patients at high risk for kidney injury, according to the results of a small retrospective study presented in poster format at the Society for ...' | | Monday, 18 April 2011 by www.renalandurologynews.com |
|
|
|
| | | ''Bayer HealthCare Pharmaceuticals announced today that the U.S. Food and Drug Administration has approved Bayer's gadobutrol injection Gadavist™ (gadobutrol), a 1.0 molar macrocyclic gadolinium-based contrast agent (GBCA) for intravenous use in ...' | | | Tuesday, 15 March 2011 by viva.vita.bayerhealthcare.de | |
|
|
|
| | | ''For spotting the tiniest metastases inside the liver, MRI with the liver-specific gadolinium-based contrast agent Primovist (gadoxetic acid) was far and away the top choice of surgeons in an eight-country multicenter study. The surgeons were given a ...' | | | Sunday, 6 March 2011 by www.searchmedica.com | |
|
|
|
| | | ''The overall objective of this study was to develop a nanoparticle formulation for dual modality imaging of head and neck cancer. Here, we report the synthesis and characterization of polymeric phospholipid-based nanomicelles encapsulating near-infrared ...' | | | Saturday, 27 November 2010 by 7thspace.com | |
|
|
|
| | | ''Covidien (NYSE:COV), a leading global provider of healthcare products, today announced it supports the U.S. Food and Drug Administration's (FDA) labeling changes for gadolinium-based contrast agents for patients with acute kidney injury or chronic, ...' | | | Friday, 10 September 2010 by investor.covidien.com | |
|
|
|
| | | '' Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic medical imaging, supports the U.S. Food and Drug Administration's (FDA) announcement requiring safety-related label changes for all gadolinium-based contrast agents to highlight the rare ...' | | | Friday, 10 September 2010 by www.radiopharm.com | |
|
|
|
| | | ''The U.S. Food and Drug Administration is requiring that gadolinium-based contrast agents (GBCAs) carry new warnings on their labels about the risk of a rare and potentially fatal condition known as nephrogenic systemic fibrosis (NSF), if the drug is ...' | | | Thursday, 9 September 2010 by www.fda.gov | |
|
|
|
| | | ''Novel gadolinium complexes could improve magnetic resonance imaging (MRI) of blood vessels, say Belgian scientists. Gadolinium complexes have a long history of use as contrast agents in MRI. Modern MRI machines operate at high magnetic fields giving ...' | | | Monday, 6 September 2010 by www.rsc.org | |
|
|
|
| | | ''Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance ...' | | | Friday, 6 August 2010 by www.medicalnewstoday.com | |
|
|
|
| | | ''Bayer Schering Pharma AG, Berlin, Germany, announced today that the Food and Drug Administration (FDA) has accepted for filing a New Drug Application to the U.S. for gadobutrol injection, a gadolinium-based contrast agent for magnetic resonance ...' | | | Wednesday, 4 August 2010 by viva.vita.bayerhealthcare.de | |
|
|
|
|
|
|
|
|
| Result Pages |
|
|
|
|
|
If an elderly but distinguished scientist says that something is
possible he is almost certainly right, but if he says that it is impossible
he is very probably wrong.
- Arthur C. Clarke |
|
|
News
top
